UNSPSC 51334421: Pinoxepin hydrochloride

This classification denotes a dopamine antagonist C23H27ClN2O2.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7KE5R66TSY, chemically known as (z)-4-(3-(2-chlorodibenz(b,e)oxepin-11-(6h)-ylidene)propyl)-1-piperazineethanol dihydrochloride, but more generally known as pinoxepin hydrochloride, which bears US NIH Compound Identifier 6433591. Most nations, for tariff and trade purposes, schedule pinoxepin hydrochloride under HS 29349990 and SITC 51579.

As of Q4 2014, PINOXEPIN HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Pinoxepin hydrochloride bears US NLM identifiers UMLS ID C2698814 and NCI Concept Code C76653. SMILES: C1CCC\2C(C1)COC3CCC(CC3/C2=C\CCN4CCN(CC4)CCO)CL.CL.CL.

UNSPSC 51334421 Pinoxepin hydrochloride is a Commodity code nominally designating a specific pharmaceutical active ingredient; however, recent state and local solicitations show little activity directly aligned with pinoxepin procurement. The three recent opportunities posted under or near this code involve naloxone (a different pharmaceutical), generic multi-source pharmaceuticals and OTC products broadly, and exploratory vendor capabilities for direct-to-manufacturer prescription programs—none of which are pinoxepin-specific purchases. The actual buying pattern under this code at state and local level remains unclear from available solicitation records.

Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through July 2023 (response deadline July 26, 2023). The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP in January 2026 (response deadline March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local facilities in Minnesota and Oregon. The Texas Health and Human Services Commission issued an RFI in April 2026 to gather market intelligence on direct-to-manufacturer prescription programs. The code shows activity across health agencies and cooperative purchasing vehicles, but no concrete state or local demand for pinoxepin itself is evident from recent postings.